Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

[Pharmacokinetics and pharmacodynamics of antifungal drugs in children].

Jullien V.

Arch Pediatr. 2011 May;18 Suppl 1:S42-7. doi: 10.1016/S0929-693X(11)70939-3. Review. French.

PMID:
21596286
2.

Antifungal treatment in pediatric patients.

Zaoutis TE, Benjamin DK, Steinbach WJ.

Drug Resist Updat. 2005 Aug;8(4):235-45. Epub 2005 Jul 27. Review.

PMID:
16054422
3.

Pharmacodynamic implications for use of antifungal agents.

Lewis RE.

Curr Opin Pharmacol. 2007 Oct;7(5):491-7. Epub 2007 Jul 9. Review.

PMID:
17616480
4.

Antifungal PK/PD considerations in fungal pulmonary infections.

Lepak AJ, Andes DR.

Semin Respir Crit Care Med. 2011 Dec;32(6):783-94. doi: 10.1055/s-0031-1295726. Epub 2011 Dec 13. Review.

PMID:
22167406
5.

Management of systemic fungal infections: alternatives to itraconazole.

Herbrecht R, Nivoix Y, Fohrer C, Natarajan-Amé S, Letscher-Bru V.

J Antimicrob Chemother. 2005 Sep;56 Suppl 1:i39-i48. Review.

PMID:
16120633
6.
7.

Treatment of Aspergillus terreus infections: a clinical problem not yet resolved.

Pastor FJ, Guarro J.

Int J Antimicrob Agents. 2014 Oct;44(4):281-9. doi: 10.1016/j.ijantimicag.2014.07.002. Epub 2014 Aug 8. Review.

PMID:
25190543
8.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
9.

[Drug interactions in critically-ill patients. An important factor in the use of micafungin?].

Garnacho-Montero J, Jiménez Parrilla F.

Enferm Infecc Microbiol Clin. 2011 Mar;29 Suppl 2:33-7. doi: 10.1016/S0213-005X(11)70007-6. Review. Spanish.

PMID:
21420575
10.

Antifungal pharmacokinetics and pharmacodynamics.

Lepak AJ, Andes DR.

Cold Spring Harb Perspect Med. 2014 Nov 10;5(5):a019653. doi: 10.1101/cshperspect.a019653. Review.

11.

Treatment of systemic fungal infections: recent progress and current problems.

Walsh TJ, Pizzo A.

Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):460-75. Review.

PMID:
2846299
12.

[Systemic antifungals. Pharmacodynamics and pharmacokinetics].

Catalán M, Montejo JC.

Rev Iberoam Micol. 2006 Mar;23(1):39-49. Review. Spanish.

13.

Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.

Stockmann C, Constance JE, Roberts JK, Olson J, Doby EH, Ampofo K, Stiers J, Spigarelli MG, Sherwin CM.

Clin Pharmacokinet. 2014 May;53(5):429-54. doi: 10.1007/s40262-014-0139-0. Review.

PMID:
24595533
14.

Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients.

Filioti I, Iosifidis E, Roilides E.

Expert Opin Pharmacother. 2008 Dec;9(18):3179-96. doi: 10.1517/14656560802560005 . Review.

PMID:
19040339
15.

[Choice and use of antifungal drugs].

Dupont B.

Rev Prat. 2001 Apr 15;51(7):752-7. Review. French.

PMID:
11387672
16.

Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations.

Smith J, Andes D.

Ther Drug Monit. 2008 Apr;30(2):167-72. doi: 10.1097/FTD.0b013e318167d0e0. Review.

PMID:
18367976
17.

Antifungal drugs.

[No authors listed]

Treat Guidel Med Lett. 2008 Jan;6(65):1-8. Review. No abstract available.

PMID:
18157085
18.

Antifungal agents in children.

Steinbach WJ.

Pediatr Clin North Am. 2005 Jun;52(3):895-915, viii. Review.

PMID:
15925667
19.

In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species.

Nishi I, Sunada A, Toyokawa M, Asari S, Iwatani Y.

J Infect Chemother. 2009 Feb;15(1):1-5. doi: 10.1007/s10156-008-0653-9. Epub 2009 Mar 12. Erratum in: J Infect Chemother. 2009 Apr;15(2):123-4.

PMID:
19280292
20.

CNS-aspergillosis: are there new treatment options?

Schwartz S, Thiel E.

Mycoses. 2003;46 Suppl 2:8-14. Review.

PMID:
15055138

Supplemental Content

Support Center